DNA RNA and Cells

16 Dec 2016 bluebird bio and apceth Biopharma Establish Commercial Drug Product Manufacturing Agreement
15 Dec 2016 Kiadis Pharma announces initiation of a Phase I/II clinical trial with ATIR201™ for thalassemia
14 Dec 2016 bluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product in Northstar-2 (HGB-207) Phase 3 Trial of Patients with Transfusion-Dependent β-Thalassemia
14 Dec 2016 TILT Biotherapeutics Secures 10 M€ ($10.6M) for Viral Cancer T-Cell Immunotherapy
14 Dec 2016 FDA approves first autologous cellularized scaffold for the repair of cartilage defects of the knee
13 Dec 2016 Dimension Therapeutics Announces FDA Acceptance of Investigational New Drug Application for DTX301 to Treat OTC Deficiency
12 Dec 2016 Kite Pharma Announces Publication of T-Cell Therapy Targeting Mutant KRAS in Cancer by the National Cancer Institute (NCI) in New England Journal of Medicine
12 Dec 2016 NantKwest Announces Enhanced High-Affinity Activated Natural Killer (haNK) Cell Therapy in Preclinical Studies of HER2 Positive Breast Cancer at Presentation at the San Antonio Breast Cancer Symposium
12 Dec 2016 Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)
07 Dec 2016 Juno Therapeutics Highlights Progress with Best-in-Class Strategy in B-Cell Malignancies at ASH
06 Dec 2016 Kite Pharma Presents Results of Multi-Center Pivotal ZUMA-1 Trial of Axicabtagene Ciloleucel (KTE-C19) in Aggressive Non-Hodgkin Lymphoma as Late-Breaking Abstract at Annual Meeting of American Society of Hematology
06 Dec 2016 Sangamo BioSciences Presents Hemophilia A Program Data At The 2016 American Society Of Hematology Meeting
06 Dec 2016 CELYAD S.A.: Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting
06 Dec 2016 Bellicum Presents Clinical Results to Date of BPX-501 Pediatric Program and Provides Regulatory Update at Investor Event During ASH Annual Meeting
06 Dec 2016 bluebird bio Provides Updates on HSC Gene Therapy Programs
06 Dec 2016 Highly promising preclinical data in leukaemia and solid tumours for CAR-CD44v6 presented at the 58th Annual Meeting of the American Society of Hematology
05 Dec 2016 Poseida Therapeutics Presents Preclinical Data Demonstrating Tumor Response from BCMA-Specific CAR-T Program at American Society of Hematology Annual Meeting
05 Dec 2016 Alnylam Presents Updated Results from Phase 1/2 Study of ALN-CC5 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
05 Dec 2016 Bellicum Pharmaceuticals Announces GoCAR-T and GoTCR Preclinical Presentations at the American Society of Hematology 2016 Annual Meeting
05 Dec 2016 Juno Therapeutics Presents Data From TRANSCEND Study Showing 60% Complete Response in Patients with Relapsed or Refractory Aggressive CD19+ Non-Hodgkin Lymphoma
05 Dec 2016 Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study
05 Dec 2016 Dynavax Presents Clinical Data from Lead Cancer Immunotherapy Candidate, SD-101, in Combination with Targeted Low-Dose Radiation, at ASH Annual Meeting
05 Dec 2016 VBL Therapeutics Announces Positive DSMC Review in Phase 3 GLOBE Trial Investigating VB-111 in rGBM
05 Dec 2016 Alnylam Reports Positive Interim Clinical Results for Fitusiran from Ongoing Phase 2 Open Label Extension Study in Patients with Hemophilia A or B without Inhibitors
05 Dec 2016 Kite Pharma Reports 82 Percent of Patients Achieved Complete Remission in Preliminary Analysis from Phase 1 ZUMA-3 and ZUMA-4 Trials of KTE-C19 in Adult and Pediatric Patients with High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing